Dr. Aravind Badiger, Technical Director at BDR Pharmaceuticals, discusses why there is a rise in heart diseases among women after menopause
Heart disease is a major health concern for women, particularly as they enter menopause. Menopause typically occurs between the ages of 45 and 55, marking the end of a woman’s reproductive years. It is characterized by a significant decline in estrogen levels, which can have profound effects on heart and blood vessel health.
Estrogen, a hormone produced by the ovaries, plays a crucial role in maintaining cardiovascular health. It helps manage cholesterol levels by increasing the levels of high-density lipoprotein (HDL) cholesterol, often referred to as “good” cholesterol, and decreasing levels of low-density lipoprotein (LDL) cholesterol, known as “bad” cholesterol. Estrogen also promotes vasodilation, which is the widening of blood vessels, and possesses anti-inflammatory properties that protect against the development of atherosclerosis, a condition characterized by the buildup of fatty deposits in the arteries.
During menopause, the reduction in estrogen levels can lead to an imbalance in cholesterol levels, with an increase in LDL cholesterol and a decrease in HDL cholesterol. This hormonal change contributes to the development of atherosclerosis, increasing the risk of heart attacks and strokes. Additionally, hormonal changes during menopause can trigger metabolic shifts that further increase the risk of heart disease.
Read More: Suffer From Migraine? Root Causes And Triggers You Should Be Aware Of
Many women tend to gain weight, especially around the abdomen, during and after menopause. This weight gain is associated with insulin resistance, a condition in which the body’s cells become less responsive to insulin, leading to higher blood sugar levels. Insulin resistance is a key risk factor for type 2 diabetes, which is itself a significant risk factor for heart disease.
Furthermore, post-menopausal women are more likely to develop metabolic syndrome, a cluster of conditions including hypertension (high blood pressure), high blood sugar, excess abdominal fat, and abnormal cholesterol levels. Metabolic syndrome further elevates the risk of heart disease, making it essential to address these risk factors in postmenopausal women.
Research presented at the American College of Cardiology’s Annual Scientific Session highlighted the concerning trend of accelerated plaque buildup in the arteries of post-menopausal women compared to men. This plaque buildup, known as coronary artery calcium (CAC), is a marker of atherosclerosis and a predictor of future cardiovascular events. Women with higher baseline CAC levels experienced a faster rate of plaque accumulation, underscoring the need for targeted interventions to reduce cardiovascular risk in postmenopausal women.
In addition to changes in cholesterol levels and metabolic factors, hormonal changes during menopause also contribute to chronic inflammation, which is a key driver of cardiovascular disease. Estrogen has anti-inflammatory properties that protect against chronic inflammation, but the decline in estrogen levels during menopause leads to higher levels of inflammatory markers, such as C-reactive protein (CRP), which are associated with an increased risk of heart disease.
Addressing the increase in heart disease among postmenopausal women requires a holistic approach that includes lifestyle modifications and, in some cases, medication. Hormone Replacement Therapy (HRT) is one option for managing menopausal symptoms and may have cardiovascular benefits if initiated around the time of menopause. However, HRT is not suitable for all women and carries potential risks, including an increased risk of breast cancer and blood clots.
In addition to HRT, medications such as antihypertensive drugs and antidiabetic medications are essential for managing high blood pressure and insulin resistance in postmenopausal women. Furthermore, ongoing research is exploring the development of anti-inflammatory agents that target inflammation pathways involved in cardiovascular disease.
The rise in heart disease among postmenopausal women is a complex interplay of hormonal, metabolic, and inflammatory changes. Pharmaceutical interventions play a crucial role in managing and reducing this risk, but a personalized approach is necessary to tailor treatment to individual needs. Personalized medicine, which considers genetic, environmental, and lifestyle factors, holds promise.
Ultimately, the power to control heart health lies in the hands of women themselves. By adopting a proactive approach to health, focusing on preventive measures such as regular exercise, a healthy diet, and stress management, women can significantly reduce their risk of heart disease after menopause. Empowering women with knowledge about their cardiovascular health and encouraging them to take charge of their well-being can lead to improved outcomes and a higher quality of life for postmenopausal women.
